Grau G E, Roux-Lombard P, Gysler C, Lambert C, Lambert P H, Dayer J M, Guillevin L
Department of Pathology, CMU, University of Geneva, Switzerland.
Immunology. 1989 Oct;68(2):196-8.
Cytokines are known to alter a number of vascular tissue cell functions. The aim of this retrospective study was to determine serum cytokine levels in patients with vasculitis and to analyse the possible relation to the severity of the disease. Tumour necrosis factor alpha (TNF alpha), interleukin-1 (IL-1)beta, IL-2, interferon (IFN)- and IFN-gamma were assayed in 33 patients with polyarteritis nodosa (PAN) or Churg and Strauss angiitis (CSA), and three with Wegener granulomatosis (WG). Serum cytokine changes were observed in most patients with active disease, i.e. before treatment was started. In the majority of patients with PAN or CSA, there was a marked increase in serum IFN-alpha and IL-2 levels, while TNF-alpha and IL-beta levels were moderately elevated. Serum IFN-gamma remained undetectable in all but one of these patients. In patients with WG, serum IFN-alpha and IL-2 levels were also elevated, whereas IL-1 beta, IFN-gamma and TNF alpha levels remained within normal limits. In paired samples of patients with PAN, IFN-alpha and IL-2 levels were significantly higher before than after treatment. These preliminary data suggest that a particular pattern of cytokine changes is associated with vasculitis and that cytokines might be involved in the pathogenesis of PAN/CSA and WG. Prospective studies are warranted to determine whether cytokines could be considered for the monitoring of disease activity and therapy.
已知细胞因子可改变多种血管组织细胞的功能。本回顾性研究的目的是测定血管炎患者的血清细胞因子水平,并分析其与疾病严重程度的可能关系。对33例结节性多动脉炎(PAN)或变应性肉芽肿性血管炎(CSA)患者以及3例韦格纳肉芽肿(WG)患者检测了肿瘤坏死因子α(TNFα)、白细胞介素-1(IL-1)β、IL-2、干扰素(IFN)-α和IFN-γ。在大多数活动性疾病患者中,即在开始治疗前,观察到血清细胞因子发生变化。在大多数PAN或CSA患者中,血清IFN-α和IL-2水平显著升高,而TNF-α和IL-1β水平中度升高。除1例患者外,所有这些患者的血清IFN-γ均未检测到。在WG患者中,血清IFN-α和IL-2水平也升高,而IL-1β、IFN-γ和TNFα水平仍在正常范围内。在PAN患者的配对样本中,治疗前IFN-α和IL-2水平显著高于治疗后。这些初步数据表明,特定的细胞因子变化模式与血管炎有关,并且细胞因子可能参与PAN/CSA和WG的发病机制。有必要进行前瞻性研究以确定细胞因子是否可用于监测疾病活动和治疗。